Sep 12, 2022 / 08:00PM GMT
Vernon Tolentino Bernardino - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst
Hi, everyone. Thanks for coming to the H.C. Wainwright Global Healthcare Conference. My name is Vernon Bernardino. I'm a senior analyst at H.C. Wainwright.
From the Novavax today, we have the privilege of having a discussion with Chief Scientific Officer, Gregor Glenn; and Chief Business Officer and Chief Commercial Officer, John Trizzino.
I think with them today, you'll get a flavor for why this is a company that's on the cusp of emerging as a true vaccine business and one that's perhaps going to be an important player that's going to grow very quickly, very soon.
So before we get -- gets into an overview of the company. Just wondering if you could go over what makes your technology -- your vaccine technology, unique and how it's different from the others out there.
Gregory M. Glenn - Novavax, Inc. - President of Research & Development
Good. Well, thanks for having us. It's great to be here. So
Novavax Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers